Vernalis
Expertise Partner
For more than 25 years Vernalis has been working with a wide range of organisations to enable drug discovery programs against some of the most challenging therapeutic targets. From protein-protein interactions to novel targets classes, we have developed a deep expertise in helping our partners identify novel, validated hits using a wide range of integrated techniques, and to take these hits forward into robust, reliable leads and candidates.
Vernalis employs a wide range of hit ID methods, including fragment-based approaches, MTS biochemical assays, computational methods and, as part of the HitGen Group, cutting-edge DEL technology. Using our in-house high field NMR, crystallography, MS, SPR and ITC facilities, we are able to rapidly identify, validate and characterise chemical series. In particular, we have a deep understanding of integrating multiple Hit ID methods to generate multiple high quality, validated hit series to progress into H2L and LO.
Our established group of experienced scientists is based at our fully-equipped research laboratories in Cambridge, UK. We combine fragment-based approaches, structural biology, DNA encoded libraries, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on enzymes, protein-protein interactions and GPCRs, with disclosed programs for inhibitors of LRRK2, Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A. Previous and on-going collaborations include Pierre Fabre, Novartis, Genentech, Servier, Lundbeck, AKP, Taisho and Daiichi Sankyo.